Canadian Nuclear Isotope Council

What Canadian Nuclear Isotope Council does

The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization established in 2018 and headquartered at 123 Front St W, Toronto. It was created to convene stakeholders across Canada's isotope supply chain — reactor operators, isotope processors, radiopharmaceutical manufacturers, healthcare providers, academic researchers, and federal/provincial government — and to advocate for policies that maintain Canada's position as a global leader in medical isotope production, a heritage dating back to the first cobalt-60 cancer treatment in 1951. The organization supports over 120 members through tiered memberships (Executive, Contributing, Academic, Health Partner, NGO/Industry) and operates flagship programs including the Isotopes for Hope campaign (launched March 2023, Phase 2 in November 2025), the Oncologist & Clinical Scientist Network (2025), the annual Radiotheranostics Leaders' Summit, the CNIC Awards, the Isotopes for Hope Podcast, and provincial sector briefings. CNIC also holds formal advisory roles with the Government of Canada's Radioisotope Strategy and Ontario's Minister's Advisory Council, and in March 2025 signed Practical Arrangements with the IAEA to support the Rays of Hope initiative.

CNIC generates revenue through annual membership dues (specific pricing not publicly disclosed) and event sponsorships, including the Novartis-sponsored Canadian Radioligand Therapy Innovation Awards. The organization runs a multi-channel advocacy and awareness strategy combining thought leadership content (reports, podcasts, webinars), events (annual summit with 500+ attendees), social media, and direct member engagement. A core staff of four (Executive Director Melody Greaves, plus managers for Public Affairs, Strategic Initiatives, and Research) executes operations. The organization does not develop proprietary technology products; its competitive position rests on network effects across its 120+ member ecosystem, embedded regulatory relationships, and the reputational equity of Canada's 70+ year isotope production history.

Name

Canadian Nuclear Isotope Council

Legal name

Canadian Nuclear Isotope Council

Website

https://canadianisotopes.ca

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

The Canadian Nuclear Isotope Council is an independent, not-for-profit advocacy organization, founded in 2018 in Toronto, that convenes 120+ member organizations across Canada's medical isotope supply chain to advocate for supportive policies, raise public awareness, and connect producers, healthcare providers, researchers, and government.

Ownership category

akta.pro rank

Product category

Industry Advocacy and Trade Association Services

NAICS

Social Advocacy Organizations (8133), Civic and Social Organizations (81341)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Medical isotope advocacy
• Nuclear sector policy
• Radiopharmaceutical ecosystem
• Industry trade association
• Healthcare isotope supply

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Membership fees: The CNIC supports over 115-120 members from across science, academia, healthcare, and nuclear-sector organizations through membership fees. Membership categories include Executive Members, Contributing Members, Academic Institutions, Foundations/Charities/Research and Health Partners, and NGO and Industry Partners.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

The Canadian Nuclear Isotope Council is an independent, not-for-profit advocacy and member services organization that convenes stakeholders across Canada's medical isotope supply chain. It provides membership programs, policy advocacy, awareness campaigns (Isotopes for Hope), networking events (Annual Leaders' Summit), awards, and educational publications for over 120 member organizations spanning isotope producers, healthcare providers, researchers, and government.

Product overview

The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization—not a product company. Its core 'offerings' are advocacy initiatives, educational resources, networking programs, and events designed to advance Canada's position as a global leader in medical isotope production. The primary offering is the Isotopes for Hope Campaign, a multi-phase advocacy initiative with an ambitious goal of doubling Canada's isotope production by 2030. Supporting programs include the Oncologist & Clinical Scientist Network (which convenes clinical leaders to advocate for expanded isotope access), the Isotopes for Hope Podcast (a content series featuring industry leaders), and the Canadian Radiotheranostics Leaders' Summit (an annual conference). The CNIC also produces Reports & Policy Papers including the annual Fact Book and provincial sector briefings, and manages the CNIC Awards program recognizing leadership in the isotope sector. All offerings are advocacy, education, and networking services rather than commercial products.

Differentiator

Problem solved

Functional benefit

Brands

• Isotopes for Hope Campaign: A campaign launched in March 2023 focused on expanding Canada's global leadership in the development, supply, and use of medical isotopes, with a goal of doubling Canada's isotope production by 2030.
• CNIC Awards
• Canadian Radiotheranostics Leaders' Summit

Products and services

• Isotopes for Hope Campaign A national advocacy campaign launched in March 2023 to expand Canada's global leadership in the development, supply, and use of medical isotopes, with a goal of doubling Canada's production by 2030 and raising awareness of the role isotopes play in modern medicine. Phase 2 was launched in November 2025 with the 'Isotopes for Hope: Canada's 2030 Promise' report.
• Canadian Radiotheranostics Leaders' Summit An annual event bringing together leaders from across the global isotope supply chain, business and investment communities, government representatives, healthcare leaders, academics, and students, co-hosted with the Canadian Medical Isotope Ecosystem (CMIE) and a consortium of academic health centres. The 2026 summit theme is 'Collaboration in action: Unleashing Canada's radioisotope future.'
• Oncologist & Clinical Scientist Network A national initiative launched in 2025 that brings together leading oncologists, nuclear medicine physicians, and clinical scientists to advance awareness of and access to medical isotopes and radiopharmaceuticals. The network is led by four Co-Chairs at leading cancer centres across Canada.
• CNIC Awards Program Annual awards recognizing individuals and organizations demonstrating significant leadership and advocacy within Canada's isotope sector, with categories including Government Stewardship, Indigenous Partnership, Ecosystem Innovation, Academic Leadership, and Health Champion.

Quantifiable outcome

• Goal to double Canada's production of medical isotopes by 2030
• +4 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

28 partnerships are on record, tiered minor and core.

• Marathon FusionminorStrategic or Co-development Partner · 10 July 2026San Francisco-based nuclear fusion startup founded in 2023 working on transmutation (neutron-driven production of radioisotopes), fuel processing, and isotope separation. CEO Kyle Schiller believes fusion is humanity's best path to abundant clean energy and valuable isotope production.
• Central and Eastern Ontario Isotope Alliance (CEOIA)coreStrategic or Co-development Partner · 3 July 2026Regional collaboration connecting municipal leaders, healthcare organizations, research institutions, isotope developers, and sector advocates around shared vision for regional isotope growth. Partners include Municipalities of Clarington and Port Hope, City of Peterborough, Counties of Northumberland, Port Hope and Renfrew, Invest Durham, Laurentis Energy Partners, CNL, Actineer, Nordion, and OPG.
• Government of Canada (Natural Resources Canada)coreStrategic or Co-development Partner · 22 June 2026Government committed to develop comprehensive Radioisotope Strategy as part of new Nuclear Energy Strategy for Canada. Strategy will address Canada's role in rapidly growing global isotope market with goal of growing Canada's market share by at least 10%.
• Novartis CanadacoreStrategic or Co-development Partner · 18 June 2026Innovative medicines company sponsoring the inaugural Novartis Canadian Radioligand Therapy Innovation Awards at the Leaders' Summit 2026, with $40,000 CAD in funding for innovative Canadian research in radioligand therapy.
• Canadians for CANDU (C4C)coreStrategic or Co-development Partner · 5 February 2026Memorandum of Understanding signed to collaborate in support of Canadian-made isotopes. CANDU technology is among the world's top isotope producers. Partnership aims to strengthen advocacy and market development for Canadian isotope production.
• Canadian Nuclear Society (CNS)coreStrategic or Co-development Partner · 16 January 2026Historic MoU signed to foster a stronger, more connected nuclear ecosystem in Canada. Aims to align expertise and expand cooperation in support of Canada's isotope supply chain through joint initiatives.
• Oncologist and Clinical Scientist NetworkcoreStrategic or Co-development Partner · 21 November 2025National initiative launched in 2025 under the Isotopes for Hope campaign, bringing together leading oncologists and clinical scientists to advance awareness and access to medical isotopes. Led by four Co-Chairs at BC Cancer, Princess Margaret Cancer Centre, Centre Hospitalier de l'Université de Montréal, and QEII Health Sciences Centre.
• TMC GroupminorStrategic or Co-development Partner · 7 August 2025North Vancouver-based manufacturer of high-purity stable isotopes joining CNIC's network of over 110 members. Expands the contingent of BC isotope producers.
• Government of Ontario (Minister's Advisory Council)coreStrategic or Co-development Partner · 30 July 2025Ontario's Minister of Energy and Mines announced establishment of CNIC-led Minister's Advisory Council and commitment to Isotopes for Hope target of doubling domestic isotope production by 2030.
• TransmutexminorStrategic or Co-development Partner · 4 June 2025Switzerland-based advanced nuclear engineering company developing high-power particle accelerator technologies (HI-BEAM platform) for radioisotope generation and nuclear waste transmutation. Brings accelerator-driven isotope production expertise.
• Conexus Nuclear Inc.minorStrategic or Co-development Partner · 16 May 2025Canadian not-for-profit corporation funded by 11 members across six countries worldwide that aims to strengthen collaboration in CANDU and advanced nuclear technologies.
• Canadian Nuclear Association (CNA)coreStrategic or Co-development Partner · 17 April 2025MoU signed to increase collaboration and alignment on nuclear isotope advocacy. Highlights shared goals in positioning Canada as a global isotope leader.
• SCK CEN (Belgian Nuclear Research Centre)minorStrategic or Co-development Partner · 21 March 2025First Belgian organization to join CNIC's international network. Belgium-based nuclear research center bringing European perspective and potential collaboration on isotope research and production.
• International Atomic Energy Agency (IAEA)coreStrategic or Co-development Partner · 4 March 2025Practical Arrangements signed in March 2025 to encourage Canadian support for IAEA's Rays of Hope initiative. The CNIC will provide expert resources to training programs for low- and middle-income countries in radiation safety, isotope production, imaging, radiochemistry, and more. Includes isotope production training at Bruce Power and hands-on training at London Health Sciences Centre and St. Josephs' Hospital.
• Nuclear Industry Association of Türkiye (NIATR)minorStrategic or Co-development Partner · 4 March 2025International membership expanding CNIC's reach to Türkiye's nuclear industry. NIATR acts as the public voice of the nuclear industry in Türkiye.
• Telix PharmaceuticalsminorStrategic or Co-development Partner · 15 November 2024Commercial-stage international biopharmaceutical company producing therapeutic and diagnostic radiopharmaceuticals. Expands CNIC's international membership and radiopharmaceutical expertise.
• Southwestern Ontario Isotope Coalition (SOIC)coreStrategic or Co-development Partner · 1 January 2023Regional coalition launched in 2023 in collaboration with CNIC's Isotopes for Hope campaign, connecting municipal governments and private sector leaders around regional isotope growth.
• Bruce PowercoreStrategic or Co-development PartnerExecutive member and Canada's only private sector nuclear generator. Annually produces 30% of Ontario's power as well as significant portion of global supply of cobalt-60 and lutetium-177. Hosts isotope production system at Bruce Power facility.
• Ontario Power Generation (OPG)coreStrategic or Co-development PartnerExecutive member operating CANDU reactors including Darlington Facility used for yttrium-90 microspheres irradiation in partnership with Boston Scientific for liver cancer treatment.
• BWXT Medical Ltd.coreStrategic or Co-development PartnerExecutive member and experienced manufacturer/supplier of both isotope technologies and critical medical isotopes and radiopharmaceuticals for research, diagnostic and therapeutic use.
• NordioncoreStrategic or Co-development PartnerExecutive member and global leader in provision of Cobalt-60, critical radioisotope used to sterilize 30% of world's single-use medical devices and for treatment of brain and breast cancer.
• ITM Isotope Technologies Munich SEcoreStrategic or Co-development PartnerExecutive member and global leader in development, production and global supply of targeted diagnostic and therapeutic radioisotopes for cancer treatment. Partnership with CNL through Actineer for actinium-225 production.
• Canadian Nuclear Laboratories (CNL)coreStrategic or Co-development PartnerExecutive member and Canadian gem of research and innovation. Formed Actineer partnership with Germany's ITM to expand production of actinium-225 in Canada. Leading research in nuclear materials and isotope innovation.
• McMaster University Nuclear Operations & FacilitiescoreStrategic or Co-development PartnerExecutive member home to Canada's most powerful neutron source. Global leader in production of iodine-125 and holmium-166, used to treat cancer patients worldwide.
• TRIUMF InnovationscoreStrategic or Co-development PartnerBusiness interface and commercialization arm connecting TRIUMF (Canada's particle accelerator centre) to private sector via industry partnerships, licensing, and company creation. Executive Committee Co-Chair of Canadian Medical Isotope Ecosystem (CMIE).
• Canadian Medical Isotope Ecosystem (CMIE)coreStrategic or Co-development PartnerCo-host of annual Canadian Radiotheranostics Leaders' Summit. Development Fund has contributed funding, jobs, and innovation to create stronger domestic isotope sector with early-stage support for promising ideas. Named CNIC MVP Award recipient 2025.
• Laurentis Energy PartnerscoreStrategic or Co-development PartnerExecutive member and co-chair of CEOIA. Partnership with Boston Scientific using OPG's Darlington Facility for yttrium-90 microspheres irradiation for liver cancer treatment.
• Kinectrics / IsoGencoreStrategic or Co-development PartnerExecutive member. Joint venture with Framatome called IsoGen implementing Isotope Production System at Bruce Power - world's first commercial scale source of lutetium-177 produced by a power reactor and first commercial stable isotope enrichment platform for ytterbium-176 in North America.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Canadians for CANDU (C4C): Advocacy coalition promoting Canadian nuclear technology and supply chains. C4C signed an MoU with CNIC in February 2026 focused specifically on Canadian-made isotopes, making it a peer in pan-Canadian nuclear advocacy with overlapping membership.
• Canadian Nuclear Society (CNS): Technical and professional society for the Canadian nuclear community. CNS signed an MoU with CNIC in January 2026 to foster a stronger nuclear ecosystem, making it a directly comparable member-based, advocacy-adjacent organization in the same geography.
• Canadian Nuclear Association (CNA): Canada's broader nuclear industry advocacy body covering the full nuclear sector (energy, isotopes, decommissioning). CNIC and CNA signed an MoU in April 2025 to align on isotope advocacy, making CNA the closest organizational analogue operating at a wider remit.
• World Council on Isotopes (WCI): Global non-profit that convened the World Isotope Congress and awarded CNIC its President's Award for leadership in the global isotope community. WCI is the most direct international peer in isotope-specific advocacy.

Broad incumbents

• World Nuclear Association: Global nuclear industry association based in London. Comparable as an international nuclear advocacy and member-services body, though CNIC is narrower in scope (isotopes only) and Canada-focused.
• Nuclear Energy Institute (NEI): US nuclear industry policy and advocacy organization representing the broader nuclear sector. NEI operates at a much larger scale and broader remit but is functionally analogous as the national nuclear advocacy body for the largest adjacent market.
• European Nuclear Society (ENS): European-wide learned society and advocacy body for nuclear science and technology. Comparable as a membership-driven nuclear advocacy organization with continental scope; analogous to CNIC at a much larger geographic scale.

Emerging players

• SCK CEN (Belgian Nuclear Research Centre): Belgium's nuclear research center and first European organization to join CNIC's network in 2025. SCK CEN is a research institution rather than advocacy body, but its membership in CNIC and isotope production activities place it as a peer-organization now operating inside CNIC's ecosystem.

Regional players

• Nuclear Industry Association of Türkiye (NIATR): Public voice of the Turkish nuclear industry that joined CNIC's network in 2025. Comparable as a national nuclear industry association but operating in Türkiye, making it a regional rather than direct competitor.
• Nuclear Industry Association (UK): Trade association for the UK civil nuclear industry. Functionally similar as a national nuclear advocacy body but operating in the UK market; useful as a regional comparison for advocacy model and member services design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/IsotopesCanada
• Facebookfacebook.com/isotopescanada
• LinkedInlinkedin.com/company/canadian-nuclear-isotope-council

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canadian Nuclear Isotope Council